Floatz logo

Lenalidomide

B-Cell Neoplasm

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

47 Active assets in the B-Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Zanubrutinib
Curis, Inc.
Phase 2BB
Cyclophosphamide
University Hospital, Basel, Switzerland
Phase 2BB
Prednisone
Curis, Inc.
Phase 2BB
Adriamycin
Curis, Inc.
Phase 2BB
Rituximab
Curis, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Lenalidomide is also rated in:

adult T-cell leukemia/lymphomaActive
BBB
Indicative · Phase 2
74 / 100
View asset →
plasma cell neoplasmActive
BBB
Indicative · Phase 3
72 / 100
View asset →
B-cell non-Hodgkin lymphomaActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →